Previous 10 |
home / stock / mmirf / mmirf news
Medmira (MMIRF): FQ2 net loss of C$0.41M.Revenue of C$0.34M (+277.8% Y/Y)Press Release For further details see: Medmira reports FQ2 results
New York, NY (1/13/2021) – As the most at-risk people begin to receive COVID-19 vaccinations, we are all looking forward to a post-pandemic world. As we transition back to something closer to normal life, however, the importance of rapid detection of any pathogen that could be hazard...
A little more than two months ago, Medmira Inc. ( MMIRF ) (MIR.V) was functionally bankrupt. It had a significant working capital deficiency with dwindling cash and traded at a penny or two on the TSX Venture, making financing options extremely difficult. Then with the COVID-19 outbreak, it fo...
Medmira ( OTC:MMIRF ): Q2 Net loss of $0.61M. More news on: MedMira Inc., Earnings news and commentary, Tech stocks news, , Read more ...
Medmira ( OTC:MMIRF ): Q1 net loss of $0.5M More news on: MedMira Inc., Earnings news and commentary, Tech stocks news, , Read more ...
Medmira ( OTC:MMIRF ): Q3 GAAP EPS of C$0.00. More news on: MedMira Inc., Earnings news and commentary, Tech stocks news, , Read more ...
Medmira ( OTC:MMIRF ): Q3 GAAP EPS of C$0.00. More news on: MedMira Inc., Earnings news and commentary, Tech stocks news, , Read more ...
Medmira ( OTC:MMIRF ): FY Net loss of $2.51M. More news on: MedMira Inc., Earnings news and commentary, Tech stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focused on the launch of MedMira's latest US FDA approved Reveal ® G4 Rapid HIV 1/2 antibody...
HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of Vice President of Business Development. Ms. Bell brings over 20 years of Business Development a...
HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira received the US FDA 510(k) clearance for the HIV-2 claim on the Reveal ® G4 Rapid HIV...